

# Pneumonia: diagnosis and management (update) Committee meeting 5

**Date:** 09/05/2024

**Location:** Virtual

Minutes: Final

Committee members present:				
Tessa Lewis (Chair)	Present for notes 1 – 8			
Sumiah Al-Azeib	Present for notes 1 – 8			
Srini Bandi	Present for notes 1 – 8			
Tom Bewick	Present for notes 1 – 8			
Dan Furmedge	Present for notes 1 – 6 part of 7			
Alastair Hay	Present for notes 1 – 8			
Dan Horner	Present for notes part of 2, 3 - 8			
Philip Howard	Present for notes 1 – 8			
Joy Okafor	Present for notes 1 – 8			
Paddy McMaster	Present for notes 1 – 8			
Mitul Patel	Present for notes 1 – 3, 6 onwards			
Kathryn Thomas	Present for notes 1 – 8			
Martin Williams	Present for notes 1 – 8			
Caroline Ward	Present for notes 1 – 7			
Dan Wootton	Present for notes 2 – 10			

In attendance:					
Steph Armstrong	Senior Health Economist	Present for notes 1 – 8			
Chris Carmona	Technical Adviser	Present for notes 1 – 8			
Simran Chawla	Public Involvement Adviser, NICE	Present for notes 1 – 4			
Chris Harris	Project Manager, NICE	Present for notes 1 – 8			
Joanna Perkin	Senior Medical Editor, NICE	Present for notes 1 – 8			
Paul Levay	Information Specialist	Present for notes 1 – 8			
Edgar Masanga	Business Analyst – Resource Impact Assessment, NICE	Present for notes 2 – 8			
Hannah Stockton	Technical Analyst	Present for notes 1 – 8			
Rachel Walsh	Technical Analyst, NICE	Present for notes 1 – 8			

Apologies:	
Jennifer Head	Lay member
Joy Okafor	Advanced Clinical Practitioner
Eric Slade	Health Economics Adviser, NICE
Nick Staples	Guideline Commissioning Manager, NICE
Avril Tucker	Pharmacist - Primary Care Antimicrobial
Marisa Lanzman	Pharmacist with ITU experience
Carole Pitkeathley	Lay member with experience of Pneumonia
Michellie Young	Technical Analyst, NICE

### 1. Welcome and introductions

The Chair welcomed Committee members and attendees to the fifth meeting on Pneumonia: diagnosis and management (update). The Committee members and attendees introduced themselves.

The Chair informed the Committee that apologies had been received. These are noted above. The minutes of the previous meeting were confirmed as a true and accurate record.

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was diagnosis and management of pneumonia.

The Chair asked everyone to verbally declare any interests. The new interests declared are outlined below:

Name	Job title	Declarations of Interest, date declared	Type of interest	Decision taken
Dan Wooton	Consultant Respiratory Physician	Member of Epic4 Guideline advisory group on the prevention of hospital acquired infections	Non- financial, Professional and personal interest	Non specific  Declare and participate  Rationale: interest relates to general hospital acquired infections
Philip	Pharmacist	Co-investigator for POC AMR	Non-	Non-specific

Howard	diagnostics in sepsis pre- and	financial,	Declare and
	early hospital admission	Professional	participate
	Platform Randomised	and personal	
	evaluation of clinical	interest	Rationale:
	Outcomes using novel		Sepsis is not
	TEChnologies to optimise		part of this
	antimicrobial Therapy		update
	(PROTECT) - NIHR Funding		
	and Awards		
	https://fundingawards.nihr.ac.		
	uk/award/NIHR156664		

The Chair and a senior member of the Developer's team noted that these and no other previously declared interests would prevent attendees from fully participating in the meeting.

2 & 3. Review question 4.1: In people in hospital with a diagnosis of community- or hospital-acquired pneumonia, what is the clinical and cost effectiveness of monitoring C-reactive protein or procalcitonin and other biomarkers (or combinations of biomarkers) in addition to clinical observation in helping to determine when to deescalate or change treatment and when to change the place of care (for example, from ICU to non-ICU care or discharge from hospital)?

#### Presentation of clinical evidence and committee discussion

The Chair introduced Hannah Stockton, Technical Analyst who presented the committee with evidence relating to biomarkers for de-escalation of care. The committee asked questions, discussed the evidence presented and drafted recommendations.

## 4. Non-invasive ventilation discussion

#### Revisit of draft recommendations and committee discussion

The Chair introduced Chris Carmona, Technical Adviser who took the committee through a short presentation on non-invasive ventilation. The committee revisited the clinical evidence and draft recommendations. A discussion followed. The Chair thanked Chris for his presentation and the committee for their contributions.

6. Review question 5.1: Are shorter durations of antibiotic treatment effective and cost-effective at treating babies, children and young people with community acquired pneumonia compared to longer treatment courses?

#### Presentation of clinical evidence and committee discussion

The Chair introduced Chris Carmona, Technical Adviser who presented clinical evidence on durations of antibiotic treatment. The committee discussed the evidence and drafted recommendations. The Chair thanked Chris for his presentation and the committee for their contributions.

#### 7. Review Protocols

The Chair introduced Chris Carmona, Technical Adviser and Rachel Walsh, Technical Analyst who presented the committee with draft review protocols. The committee discussed these and asked questions, for the developer team to refine them.

## 8. AOB and next steps

There was no other business. Chris Harris, Project Manager, outlined the next steps for the committee and gave a brief reminder on future meetings and timelines. The Chair thanked those present and closed the meeting.

Date of next meeting: 20/06/2024

**Location of next meeting:** Virtual